Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: Studies with the hepatic NADPH:Cytochrome P450 reductase null mouse

Toxicology and Applied Pharmacology

Volumn 226, Issue 3, 2008, Pages 318-327

  Stiborová, Marie ^a   Arlt, Volker M ^b   Henderson, Colin J ^c   Wolf, C Roland ^c   Kotrbová, Věra ^a   Moserová, Michaela ^a   Hudeček, Jiří ^a   Phillips, David H ^b   Frei, Eva ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

32P postlabelling; Anticancer drug; Cytochrome P450; DNA adducts; Ellipticine; Peroxidase

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A; CYTOCHROME P450 3A; CYTOCHROME P450 REDUCTASE; ELLIPTICINE; LIVER ENZYME; PEROXIDASE; PHOSPHORUS 32; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER; COLON; CONTROLLED STUDY; DNA ADDUCT; DNA BINDING; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; KIDNEY; LIVER; LIVER CELL; LIVER MICROSOME; LUNG; MALE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SPLEEN; STRAIN DIFFERENCE; TISSUE DISTRIBUTION; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP3A; DNA; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELLIPTICINES; GENE SILENCING; HEPATOCYTES; INJECTIONS, INTRAPERITONEAL; ISOTOPE LABELING; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSOMES, LIVER; NADPH-FERRIHEMOPROTEIN REDUCTASE; PHOSPHORUS RADIOISOTOPES;

MUS; RATTUS;

EID: 38649108546     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.09.017     Document Type: Article

References (46)

1. Aimová D., Svobodová L., Kotrbová V., Mrázová B., Hodek P., Hudeček J., Václavíková R., Frei E., and Stiborová M. The anticancer drug ellipticine is a potent inducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism. Drug Metab. Dispos. 35 (2007) 1926-1934
2. Arlt V.M., Stiborová M., Hewer A., Schmeiser H.H., and Phillips D.H. Human enzymes involved in the metabolic activation of the environmental contaminant 3-nitrobenzanthrone: evidence for reductive activation by human NADPH:cytochrome P450 reductase. Cancer Res. 63 (2003) 2752-2761
3. Arlt V.M., Hewer A., Sorg B.L., Schmeiser H.H., Phillips D.H., and Stiborová M. 3-Aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone, forms DNA adducts after metabolic activation by human and rat liver microsomes: evidence for activation by cytochrome P450 1A1 and P450 1A2. Chem. Res. Toxicol. 17 (2004) 1092-1101
4. Arlt V.M., Stiborová M., Henderson C.J., Osborne M.R., Bieler C.A., Frei E., Martinek V., Sopko B., Wolf C.R., Schmeiser H.H., and Phillips D.H. Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols. Cancer Res. 65 (2005) 2644-2652
5. Arlt V.M., Henderson C.J., Wolf C.R., Schmeiser H.H., Phillips D.H., and Stiborová M. Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases. Cancer Lett. 234 (2006) 220-231
6. Auclair C. Multimodal action of antitumor agents on DNA: the ellipticine series. Arch. Biochem. Biophys. 259 (1987) 1-14
7. Bořek-Dohalská L., Frei E., and Stiborová M. DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect. Czech. Chem. Commun. 69 (2004) 603-615
8. Branfam A.R., Bruni R.J., Reihold V.N., Silveira D.M., Chadwick M., and Yesair D.W. Characterization of metabolites of ellipticine in rat bile. Drug Metab. Dispos. 6 (1978) 542-548
9. Buters J.T., Sakai S., Richter T., Pineau T., Alexander D.L., Savas U., Doehmer J., Ward J.M., Jefcoate C.R., and Gonzalez F.J. Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 1977-1982
10. Buters J.T., Mahadevan B., Quintanilla-Martinez L., Gonzalez F.J., Greim H., Baird W.M., and Luch A. Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor formation. Chem. Res. Toxicol. 15 (2002) 1127-1135
11. Chadwick M., Silveira D.M., Platz B.R., and Hayes D. Comparative physiological disposition of ellipticine in several animal species after intravenous administration. Drug Metab. Dispos. 6 (1978) 528-541
12. 32P-postlaeling, and GC/MS detection of 4-aminobiphenyl-DANN adducts in human peripheral lung in relation to metabolic activation pathways involving pulmonary N-oxidation, conjugation, and peroxidation. Mutat. Res. 378 (1997) 97-112
13. Eling T.E., and Curtis J.F. Xenobiotic metabolism by prostaglandin H synthase. Pharm. Ther. 53 (1992) 261-273
14. Eling T.E., Thompson D.C., Foureman G.L., Curtis J.F., and Hughes M.F. Prostaglandin H synthase and xenobiotic oxidation. Annu. Rev. Pharmacol. Toxicol. 30 (1990) 1-45
15. Fossé P., René B., Charra M., Paoletti C., and Saucier J.M. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol. Pharmacol. 42 (1992) 590-595
16. Frei E., Bieler C.A., Arlt V.M., Wiessler M., and Stiborová M. Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem. Pharmacol. 64 (2002) 289-295
17. Froelich-Ammon S.J., Patchan M.W., Osheroff N., and Thompson R.B. Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J. Biol. Chem. 270 (1995) 14998-15004
18. Gonzalez F.J., and Kimura S. Understanding the role of xenobiotic-metabolism in chemical carcinogenesis using gene knockout mice. Mutat. Res. 477 (2001) 79-87
19. Henderson C.J., and Wolf C.R. Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology. Mol. Interv. 3 (2003) 331-343
20. Henderson C.J., Otto D.M.E., Carrie D., Magnuson M.A., McLaren A.W., Rosewell I., and Wolf C.R. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J. Biol. Chem. 278 (2003) 13480-13486
21. Henderson C.J., Pass G.J., and Wolf C.R. The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity. Toxicol. Lett. 162 (2006) 111-117
22. Kimura S., Kawabe M., Ward J.M., Morishima H., Kadlubar F.F., Hammons G.J., Fernandez-Salguero P., and Gonzalez F.J. CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice. Carcinogenesis 20 (1999) 1825-1830
23. Kimura S., Kawabe M., Yu A., Morishima H., Fernandez-Salguero P., Hammons G.J., Ward J.M., Kadlubar F.F., and Gonzalez F.J. Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2. Carcinogenesis 24 (2003) 583-587
24. Monnot M., Mauffret O., Simon V., Lescot E., Psaume B., Saucier J.M., Charra M., Belehradek Jr. J., and Fermandjian S. DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J. Biol. Chem. 25 (1991) 1820-1829
25. Noguchi N., Nakano K., Aratani Y., Koyama H., Kodama T., and Niki E. Role of myeloperoxidase in the neutrophil-induced oxidation of low density lipoprotein as studied by myeloperoxidase-knockout mouse. J. Biochem. (Tokyo) 127 (2000) 971-976
26. Pass G.J., Carrie D., Boylan M., Lorimore S., Wright E., Houston B., Henderson C.J., and Wolf C.R. Role of hepatic cytochrome P450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome P450 reductase null mouse. Cancer Res. 65 (2005) 4211-4217
27. Poljaková J., Dračínský M., Frei E., Hudeček J., and Stiborová M. The effect of pH on peroxidase-mediated oxidation of and DNA-adduct formation by ellipticine. Collect. Czech. Chem. Commun. 71 (2006) 1169-1185
28. Poljaková J., Frei E., Gomez J.E., Aimová D., Eckschlager T., Hraběta J., and Stiborová M. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett. 252 (2007) 270-279
29. Rendic S., and DiCarlo F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29 (1997) 413-480
30. Singh M.P., Hill G.C., Peoch D., Rayner B., Inabach J.L., and Lown J.W. High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33 (1994) 10271-10285
31. Slepneva I.A., Sergeeva S.V., and Khramtsov V.V. Reversible inhibition of NADPH-cytochrome P450 reductase by alpha-lipoic acid. Biochem. Biophys. Res. Commun. 214 (1995) 1246-1253
32. Stiborová M., Frei E., Schmeiser H.H., and Anzenbacher P. The role of peroxidases in the activation of chemical carcinogens. Drug Metab. Interact. 9 (1991) 177-190
33. Stiborová M., Bieler C.A., Wiessler M., and Frei E. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem. Pharmacol. 62 (2001) 675-684
34. Stiborová M., Martínek V., Rýdlová H., Hodek P., and Frei E. Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res. 62 (2002) 5678-5684
35. 32P-postlabeling. Int. J. Cancer 107 (2003) 885-890
36. Stiborová M., Stiborová-Rupertová M., Bořek-Dohalská L., Wiessler M., and Frei E. Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem. Res. Toxicol. 16 (2003) 38-47
37. 2-oxide. Cancer Res. 64 (2004) 8374-8380
38. Stiborová M., Frei E., Hodek P., Wiessler M., and Schmeiser H.H. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int. J. Cancer 113 (2005) 189-197
39. Stiborová M., Bořek-Dohalská L., Aimová D., Kotrbová V., Kukačková K., Janouchová K., Rupertová M., Ryšlavá H., Hudeček J., and Frei E. Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems. Gen. Physiol. Biophys. 25 (2006) 245-261
40. Stiborová M., Dračínská H., Hájková J., Kadeřábková P., Frei E., Schmeiser H.H., Souček P., Phillips D.H., and Arlt V.M. The environmental pollutant and carcinogen 3-nitrobenzanthrone and its human metabolite 3-aminobenzanthrone are potent inducers of rat hepatic cytochromes P450 1A1 and -1A2 and NAD(P)H:quinone oxidoreductase. Drug Metab. Dispos. 34 (2006) 1398-1405
41. Stiborová M., Poljaková J., Ryšlavá H., Dračínský M., Eckschlager T., and Frei E. Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int. J. Cancer 120 (2007) 243-251
42. Stiborová M., Rupertová M., Aimová D., Ryšlavá H., and Frei E. Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology 236 (2007) 50-60
43. Tsuneoka Y., Dalton T.P., Miller M.L., Clay C.D., Shertzer H.G., Talaska G., Medvedovic M., and Nebert D.W. 4-Aminobiphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(+/+) mice. J. Natl. Cancer Inst. 95 (2003) 1227-1237
44. Ueng Y.-F., Kuwabara T., Chun Y.-J., and Guengerich F.P. Cooperativity in oxidation catalyzed by cytochrome P450 3A4. Biochemistry 36 (1997) 370-381
45. Uno S., Dalton T.P., Derkenne S., Curran C.P., Miller M.L., Shertzer H.G., and Nebert D.W. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol. Pharmacol. 65 (2004) 1225-1237
46. Yasukochi Y., Peterson J.A., and Masters B. NADPH-cytochrome c (P450) reductase: spectrophotometric and stopped flow kinetic studies on the formation of reduced flavoprotein intermediates. J. Biol. Chem. 254 (1979) 7097-7104